Talk:PD-1 and PD-L1 inhibitors
 | This article is rated Start-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | ||||||||||
| |||||||||||
Should give more weight to PD-1 inhibitors ?[edit]
More of them have been approved eg by the FDA, yet this article seems to ignore their existence. - Rod57 (talk) 21:31, 12 June 2016 (UTC)
May be able to use on mCRC (eg with MEK-inhibitors)[edit]
Anti-PD-L1 immunotherapy responsive in microsatellite-stable mCRC comb with MEK inhibition. une 2016 says it can be helpful to use them with MEK-inhibitors for mCRC types that have previously been hard to treat with immunotherapies. - Rod57 (talk) 21:22, 2 July 2016 (UTC)
Adverse effects should mention hyperprogressive disease[edit]
Adverse effects section should mention hyperprogressive disease' per Hyperprogressive Disease in Patients With Advanced Non–Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy - Rod57 (talk) 17:00, 21 September 2018 (UTC)